Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vatelizumab

Drug Profile

Vatelizumab

Alternative Names: CHR-1103; GBR 500; SAR 339658; TMC-2003; UNII-A4R7G50030

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chromos Molecular Systems
  • Developer Glenmark Pharmaceuticals S.A.; Sanofi
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Cell adhesion molecule inhibitors; Immunosuppressants; Integrin alpha2beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • No development reported Cancer
  • Discontinued Chronic obstructive pulmonary disease; Multiple sclerosis; Retinal disorders; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Jul 2016 Sanofi terminates a phase II/III trial in Multiple sclerosis based on the planned interim analysis (NCT02222948)
  • 01 Jan 2016 Vatelizumab is available for licensing as of 01 Jan 2016. http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top